DTC Held Hostage? FDA Pre-Review of TV Ads May Delay Rx Campaigns
This article was originally published in RPM Report
Executive Summary
FDA is proposing changes to its regulation of television advertising for prescription drugs with a mandatory pre-review of ads for certain products. The agency says it has the resources to complete all reviews on time. But stakeholders worry that the draft requirements would delay campaigns and make DTC advertising more expensive. It’s not like there’s a good alternative: jumping the gun on DTC carries its own set of risks.